Last reviewed · How we verify
Pertuzumab and trastuzumab FDC subcutaneous
Pertuzumab and trastuzumab FDC subcutaneous is a Small molecule drug developed by David Garcia Cinca. It is currently in Phase 2 development.
At a glance
| Generic name | Pertuzumab and trastuzumab FDC subcutaneous |
|---|---|
| Sponsor | David Garcia Cinca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (PHASE1, PHASE2)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (PHASE3)
- Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (PHASE2)
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC (PHASE2)
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHASE2)
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pertuzumab and trastuzumab FDC subcutaneous CI brief — competitive landscape report
- Pertuzumab and trastuzumab FDC subcutaneous updates RSS · CI watch RSS
- David Garcia Cinca portfolio CI
Frequently asked questions about Pertuzumab and trastuzumab FDC subcutaneous
What is Pertuzumab and trastuzumab FDC subcutaneous?
Pertuzumab and trastuzumab FDC subcutaneous is a Small molecule drug developed by David Garcia Cinca.
Who makes Pertuzumab and trastuzumab FDC subcutaneous?
Pertuzumab and trastuzumab FDC subcutaneous is developed by David Garcia Cinca (see full David Garcia Cinca pipeline at /company/david-garcia-cinca).
What development phase is Pertuzumab and trastuzumab FDC subcutaneous in?
Pertuzumab and trastuzumab FDC subcutaneous is in Phase 2.